Abacus Health Products, Inc. (CSE: ABCS) (“Abacus” or the “Company”), the company offering CBDMEDIC, the first family of topical medications combining active pharmaceutical ingredients with hemp extract and other natural moisturizers, has announced the national launch of 10 over-the-counter (OTC) pain relief products. CBDMEDIC’s innovative formula is built on 15 years of pharmaceutical research and development.
CBDMEDIC products are available across the U.S., including select CVS locations, regional and independent pharmacies including Hartig Drug and will soon be available in a growing number of grocery chains and natural product retailers. The products are also available for purchase online.
“CBDMEDIC products were developed to bring superior relief to the millions of Americans in pain,” said Perry Antelman, CEO of Abacus Health Products, which developed and distributes CBDMEDIC. “The products conform to federal requirements for OTC topical medications and, according to health care practitioners that have provided the Company’s technology to their patients, are highly effective, as reported by healthcare practitioners nationwide*. These are groundbreaking medications, and we look forward to helping millions of Americans in pain.”
A proprietary, patent-pending technology developed by the company which provides superior performance, as reported by healthcare practitioners nationwide in a survey commissioned by the Company and conducted by Surveys & Forecasts, LLC. Feedback from the healthcare practitioners affirms the efficacy of the CBDMEDIC pain relief technology and revealed that:
- 9 out of 10 healthcare practitioners who use the pain relief technology inside of CBDMEDIC say that the technology provides “more effective pain relief for their patients than other over-the-counter topical analgesics” (pain relief products).
- 9 out of 10 healthcare practitioners who use the pain relief technology inside of CBDMEDIC prefer it to other topical pain products.
“Healthcare practitioners who are using this technology have reported long-lasting pain relief over other products in their same class on the market,” continued Antelman. “Management’s internal figures show that more than 10,000 healthcare practitioners in the United States have been using and selling our pain relief technology. This response is promising as we expand our portfolio and reach the national consumer market.”
The CBDMEDIC pain-relief line offers solutions for sports-related joint and muscle pain, back and neck pain, arthritis-related pain, stiffness and swelling, and muscle and joint pain. MSRP prices begin at $39.99 and products include:
- CBDMEDIC Active Sport Solid Sport Stick
- CBDMEDIC Active Sport Deep Muscle Rub Ointment
- CBDMEDIC Arthritis Moisturizing Hand Cream
- CBDMEDIC Arthritis Deep Joint Rub
- CBDMEDIC Back & Neck Deep Rub Ointment
- CBDMEDIC Massage Deep Absorbing Oil
- CBDMEDIC Muscle & Joint Deep Rub Ointment 10-Pack
- CBDMEDIC Muscle & Joint Medicated Pain Spray
- CBDMEDIC Foot Pain Deep Rub Ointment
- CBDMEDIC Foot Pain Solid Stick
All CBDMEDIC products are OTC-registered topical medications produced in a Current Good Manufacturing Practice (cGMP) inspected facility to ensure high quality control standards.
*Data is based on a third-party survey with 253 respondents. Health Care Practitioners are primarily composed of Chiropractors, Message Therapists, Acupuncturists and Physical Therapists.
This news release contains forward-looking statements or information (collectively, “forward-looking statements”) within the meaning of applicable securities legislation. Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond the Company’s control, that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Forward-looking statements contained in this news release include, without limitation, statements pertaining to the launch of new products, the proposed distribution and sales channels of the Company, and the execution of the Company’s growth strategy.
The forward-looking statements contained in this news release are based on management’s current expectations and are subject to a number of risks, uncertainties and assumptions, including assumptions regarding the Company’s ability to efficiently operate its business, market and economic conditions, business prospects or opportunities, future plans and strategies, anticipated events and trends, and regulatory changes that may affect the Company and its customers and industry. There can be no assurance that actual results will not differ materially from those expressed or implied in forward-looking statements. Undue reliance should not be placed on forward-looking statements. Additional information about these risks, uncertainties and assumptions is contained under “Risk Factors” in the Company’s listing statement – Form 2A dated January 29, 2019, which is available under the Company’s SEDAR profile at www.sedar.com. Each forward-looking statement speaks only as of the date hereof, and the Company undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.
Neither the Canadian Securities Exchange (operated by CNSX Markets Inc.) nor its Regulation Service Provider accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Abacus Health Products
Bleckwen Raises $10m and Appoints David Christie as CEO
Bleckwen, a provider of real-time analytics software for fraud detection & prevention in payments, has come out of stealth to announce a $10 million first funding round. The funding will be used to support Bleckwen’s international expansion and the continued development of the company’s exciting software capabilities in AI-based fraud detection. The company’s expertise is strategically focused on the wider anti-money laundering (AML) and counter-terrorism financing (CTF) context. Bleckwen recently spun-off from Ercom, the French cybersecurity firm. The round was led by Ring Capital, a Paris-based venture capital firm and existing investors, including TempoCap, Bpifrance and Ineo, alongside senior management.
Built with banks, for banks, Bleckwen’s real-time, dynamic behavioural analytics & explainable AI-engine is well placed to detect the surging fraud threats in payments, such as authorised push payment fraud or the “human hack” which is growing by circa 60% year-on-year, driven by the surge in real-time payment networks globally. The platform also protects banks from the emergent risks of open banking under PSD2, where banks will no longer have full control of the end-to-end user experience and security perimeter, presenting a completely new threat dimension.
Over the last year, the company has also strengthened its management team with the hire of David Christie, a 20-year veteran in financial services, previously the COO of Euronet’s money transfer business, which included the brands Ria, HiFX and XE. David is also Chairman of VitessePSP and investor in Shieldpay, bringing with him a wealth of experience implementing and operating both fraud and AML systems in payment businesses.
David is also joined by Matt Knowles, who was recently appointed Chairman of Bleckwen. Matt was previously CEO of HiFX, and together he and David successfully scaled HiFX into a world leading international payments company prior to its successful sale to Euronet.
David Christie, Bleckwen’s CEO, commented: “Nearly $4 trillion is stolen and laundered through banks annually – circa 3% of global GDP. Existing technologies are just not cutting it in the fight against this scourge of society. Something else needs to be done and at Bleckwen, we have made tremendous progress over the last two years as part of the Ercom Group, developing solutions to bring the fight to these criminals.”
“This fundraising is confirmation of our ‘scale-up readiness’ and the support from Ring Capital and our existing investors is testament to our expertise in productising class-leading AI-based analytics in the fight against financial crime for banks. Using Bleckwen’s software, we are seeing false positive ratios drop by over 95%, the time taken to resolve alerts fall by over 50%, and a reduction in fraud loss ratios by over 60% – as compared with incumbent legacy-based rules systems.”
“Working very closely with our customers, which include a tier-1 global bank, we have developed a market-leading, payment-type agnostic, real-time capability to meet their fraud detection and prevention requirements at industrial scale. Bleckwen’s software can also dynamically adapt to ever-changing customer behaviours and profiles. We have also significantly strengthened our senior management team and operational infrastructure and will be opening offices in the UK and the US in 2019.”
Matt Knowles, TempoCap Partner and Bleckwen Chairman, commented: “Having co-founded and scaled an international payments company that processed $20 billion annually, I have extensive real-world experience of the challenges faced by both fintechs and banks in of the domain of fraud detection and AML. I have been deeply impressed by Bleckwen’s advanced use of machine learning technology to radically increase fraud detection over current solutions, but, as importantly, substantially reduce the volume of false positives (which build friction and cost into the customer journey). We see significant potential to commercialise this technology across banks, fintechs & other multi-national enterprises to help combat fraud and AML risk across all payment types.”
Nicolas Celier, co-founder of Ring capital, commented: “Bleckwen has appeared to us as the unique combination of state-of-the-art AI technology, built by a leading French data team, together with top international management with a solid track record of scaling up Fintech companies worldwide. Ring knew Bleckwen before the spin-off and has contributed to design this deal in order to help Bleckwen grow and scale.”
Thierry Sommelet, Managing Director at Bpifrance Growth Capital – Head of Technology, Media, Telecom, said: “Bleckwen is uniquely positioned to help the fast-moving payments ecosystem improve clients’ protection and transaction efficiency, thanks to a leading-edge AI technology and experienced management. We are very happy to see David Christie and Matt Knowles join this adventure, as well as Ring Capital. We are confident that they will collectively thrive in driving the company on its new phase of growth.”
Bleckwen was recently awarded Fintech of the year at the EBAday 2019, an event run by the Euro Banking Association – an expert-led forum for the European payments industry with nearly200 member banks. Selected out of a category of 16 other finalists, the company received the prestigious award based on the innovative and dynamic nature of its market-leading AI-powered platform.
KLoBot – An Enterprise Chatbot Builder Platform launches Twilio Integration to Enhance Customer Experience
KLoBot – a DIY Chatbot platform is pleased to set in motion the much-awaited integration to Twilio. With technology and social media enabling an always-on approach to business, customer expectations have been higher. Voice and Text enabled chatbots empower customer-facing organizations across numerous industries to communicate and engage with every end user seamlessly.
To learn more about KLoBot, visit us online – www.klobot.ai
“Businesses must support ease of chatbot interactions for their customers using traditional communication such as a simple phone call or text messaging,” said Ragav Jagannathan, Founder of KLoBot, Inc. “With KLoBot based chatbots readily available on Twilio platform, businesses can offer their customers 24/7 first line of support using a simple voice call or SMS to a phone number and automatically have chatbot respond to their query.”
Customers can get access to information ‘on-demand’ via a simple text message or voice call in real time. These cutting edge, no-code chatbots streamline communication and enhance customer engagement. If the requests get complicated, they are smoothly transitioned from bots to human via KLoBot’s ‘Live Agent Handoff’ skill. Watch Video
KLoBot and Twilio, together, will allow companies to manage customer relationship via automating routine tasks and processes. Early adopters of KLoBot can drastically save operation costs, improve sales, offer personalized customer service and in turn, gain a sustainable competitive advantage by discovering the benefits of this KLoBot and Twilio compelling integration.
SOURCE KLoBot, Inc.
Synopsys and GLOBALFOUNDRIES Collaborate to Develop Broad Portfolio of DesignWare IP for 12LP FinFET Process
- DesignWare IP portfolio for GLOBALFOUNDRIES 12LP FinFET process includes Multi-Protocol 25G, USB 3.0 and 2.0, PCI Express 2.0, DDR4, LPDDR4/4X, MIPI D-PHY, SD-eMMC, and Data Converters
- Synopsys’ DesignWare IP are optimized for high performance and low latency in compute-intensive applications, such as artificial intelligence, high-end smartphones, and networking infrastructure
- Long-standing collaboration between the two companies has resulted in the successful development of DesignWare IP from 180-nm to 12-nm
Synopsys, Inc. (Nasdaq: SNPS) today announced its collaboration with GLOBALFOUNDRIES (GF) to develop a broad portfolio of DesignWare® IP, including Multi-Protocol 25G, USB 3.0 and 2.0, PCI Express® 2.0, DDR4, LPDDR4/4X, MIPI D-PHY, SD-eMMC, and Data Converters, for GF’s 12-nanometer (nm) Leading-Performance (12LP) FinFET process technology. Synopsys’ DesignWare IP on the GF 12LP process enables designers to implement the latest interface and analog IP solutions in their artificial intelligence (AI), cloud computing, mobile, and consumer system-on-chips (SoCs) on GF’s 12LP technology, which delivers a 10 percent improvement in logic density and more than a 15 percent improvement in performance compared to previous FinFET generations. This collaboration is another extension to the long-standing relationship between the two companies, which has delivered DesignWare IP for GF’s processes from 180-nm to 12-nm.
“In response to growing demand for differentiated, feature-rich FinFET offerings, we are collaborating with Synopsys to provide quality IP in GF’s processes, enabling designers to deliver differentiated products to a broad set of market segments,” said Mark Ireland, vice president of Ecosystem Partnerships at GF. “The combination of our 12LP process with 3D FinFET transistor technology and Synopsys’ high-performance DesignWare IP allows our mutual customers to accelerate their time to volume production.”
“As the leading provider of interface IP, Synopsys continues to collaborate with key foundries, such as GF, to deliver DesignWare IP solutions for the latest FinFET process technologies,” said John Koeter, vice president of marketing for IP at Synopsys. “With Synopsys’ DesignWare IP portfolio in GF’s 12LP process, designers can efficiently integrate the necessary functionality into their complex SoCs while meeting the bandwidth and power requirements of their mobile and high-end computing applications.”
SOURCE Synopsys, Inc.
Blockchain3 months ago
XWallet crosses 100,000 registered users
Blockchain2 months ago
Australian Fintech Nauticus Targets $25 Million in Equity Raise
Latest News3 months ago
Rossi Is Betting on the Future
Latest News3 months ago
INOX Opens its Third Multiplex in Chennai at OMR
Latest News3 months ago
Wirecard Joins Retailtech Hub – Powered by MediaMarktSaturn and Plug and Play – to Empower Future Commerce Innovation
Blockchain1 month ago
RACE-CAP™ Launches RACE-PAY™, the First of Its Digital Money Apps for Everyone
Blockchain4 weeks ago
TRON Announces BitTorrent File System Protocol
Blockchain1 month ago
Bitcoin Association’s Bitcoin SV Hackathon Finalists Announced in Lead Up to CoinGeek Toronto Conference